Omalizumab: experience in children with severe asthma living in the Rostov region

O.E. Semernik, A.A. Lebedenko, T.D. Tarakanova, S.V. Maltsev, E.B. Tyurina, N.U. Shvydchenko 

Federal State Budgetary Institution of Higher Education «Rostov State Medical University» of the Ministry of Health of the Russian Federation, Rostov-on-Don, Russia

ALLERGOLOGY AND IMMUNOLOGY IN PEDIATRICS, Volume 58 • Number 3 • September 2019, pp. 33 – 38
DOI: 10.24411/2500-1175-2019-00015

According to epidemiological studies, it has been shown that the incidence of severe asthma is currently around 5-10%. At the same time the volume of therapeutic interventions necessary to achieve control over the disease in these patients deserves special attention. Since most of them are refractory to traditional therapy, the addition of genetically engineered drugs, such as Omalizumab, is necessary in their treatment plan.
Objective: to evaluate clinical and functional parameters in patients with severe atopic asthma living in the Rostov region receiving immunobiological therapy with omalizumab.
Materials and methods: Dynamic observation was conducted for patients with severe asthma (n = 20) receiving omalizumab as part of basic therapy. The analysis of clinical and laboratory parameters in the dynamics of two years of therapy was carry out.
Results: There is an improvement in the clinical picture of the disease: decrease in the frequency of day and night attacks, accompanied by an increase in the AST test in all patients (before therapy, the AST value was 14.17 ± 6.05 points, while after 2 years of treatment with omalizumab – 21.33 ± 2.88 points [p = 0.048]). The use of anti-IgE-therapy leads to an improvement in the function of external respiration: peak expiratory velocity, forced expiratory volume for 1 minute.
Conclusion: The purpose of this genetically engineered drug leads to a significant reduction in the volume of basic therapy in patients with asthma.

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2018. Global Initiative for Asthma (GINA). Availablefrom: http://www.ginasthma.org.
  2. Трофименко C.Л., Ракова К.А. Заболеваемость поллинозом в Ростове-на-Дону // Российская ринология. 2015. № 1.  С. 36–39.
  3. Национальная программа: Бронхиальная астма у детей. Стратегия лечения и профилактика. 5-е изд., перераб. и доп. М.: Оригинал-макет, 2017. 160 с.
  4. Фармакоэкономический анализ применения омализумаба у детей, больных тяжелой неконтролируемой бронхиальной астмой: данные реальной клинической практики в России / А.С. Колбин, Л.С. Намазова-Баранова, Е.А. Вишнёва и др. // Педиатрическая фармакология. 2016. Т. 13, № 4.  С. 345–353.
  5. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma / J. Bousquet, E. Mantzouranis, A.A. Cruz et al. // J. Allergy Clin. Immunol. 2010. Vol. 126, № 5. P. 926–938.
  6. Аджимуллаева А.З., Синицина Н.В. Клиническое исследование высокотехнологической медицинской помощи с использованием генно-инженерного препарата Ксолар в терапии тяжелой формы бронхиальной астмы // Бюллетень медицинских интернет-конференций. 2018. Т. 8, № 5. С. 216.
  7. Власова Ю.А., Машкарина Т.В. Терапия Ксоларом – катамнез больных бронхиальной астмой // Бюллетень медицинских интернет-конференций. 2013. Т. 3, № 3.  С. 712.
  8. New perspectives of childhood asthmatreatment with biologics / J. Just, A. Deschildre, S. Lejeune et al. // Pediatr. Allergy Immunol.2019.  Vol. 30, № 2. P. 159–171. doi: 10.1111/pai.13007.
  9. Clinical impact of omalizumabtreatment in childrenwith severe asthma: Report of a local experience / V. Giubergia,  M.J. Ramírez Farías, V. Pérez et al. // Arch. Argent. Pediatr.  2019. Vol. 117, № 2. e115-e120. doi: 10.5546/aap.2019.eng.e115.
  10. ‘Real-life’ experience in asthmatic childrentreated with omalizumabup to six-years follow-up. / M.M. Folqué, J. Lozano, C. Riggioni et al. // Allergol. Immunopathol.  2019. Vol. 47, № 4. P. 336–341. doi: 10.1016/j.aller.2018.09.009.
  11. Omalizumaband unmet needs in severe asthmaand allergic comorbidities in Japanese children / S. Nishima, M. Kozawa, K.L. Milligan et al. // Asia Pac. Allergy. 2019, Jan 22. Vol. 9, № 1. e 7. doi: 10.5415/apallergy.2019.9.e7. eCollection 2019 Jan.
  12. Комплексная клинико-экономическая экспертиза применения омализумаба при тяжелой неконтролируемой бронхиальной астме в России / А.С. Колбин, Л.С. Намазова-Баранова, Е.А. Вишнева и др. // Клиническая фармакология и терапия. 2016. Т. 25, № 5. С. 80–85.

Semernik OE, Lebedenko AA, Tarakanova TD, Maltsev SV, Tyurina EB, Shvydchenko NU. Omalizumab: experience in children with severe asthma living in the Rostov region. Allergology and Immunology in Pediatrics. 2019;58(3):33-38. (In Russ.) https://doi.org/10.24411/2500-1175-2019-00015

For correspondense

O.E. Semernik
e-mail: semernick@mail.ru

A.A. Lebedenko
e-mail: leb.rost@rambler.ru

T.D. Tarakanova
e-mail:dr-tarakanov@yandex.ru

S.V. Maltsev
e-mail: steve30@yandex.ru

E.B. Tyurina
e-mail:elena_b_t@mail.ru

N.U. Shvydchenko
e-mail:kdb2_rostgmu@mail.ru

ALLERGOLOGY and IMMUNOLOGY in PEDIATRICS

Spelling error report

The following text will be sent to our editors: